1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cardiolynx AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Cardiolynx AG (Cardiolynx) is a pharmaceutical and healthcare company. . It manufactures pharmaceutical products that focus on the therapeutic area of cardiovascular diseases that includes Nitric Oxide (NO) in vascular health, Angina pectoris (AP), Peripheral Artery Disease (PAD) and Type 2 Diabetes Mellitus. The product pipelines that the company offers include fixed dose combinations (pharmaceutical formulations that contain two or more individual active substances) and hybrid molecules (novel bi-functional molecules that combine two separate activities into a single compound). Its lead compounds that is small organic nitrate with vasodilatory potential similar to archetype, nitroglycerin include CLC-1201(series of compounds based on valsartan that is an angiotensin receptor blocker), CLC-2001 (amalgamation of an organic nitrate and cilostazol) and CLC-3001 (pioglitazone as a hybrid molecule that is an insulin-sensitizing agent). It focuses on optimizing medical treatment of cardio-metabolic diseases. The company operates across Europe. Cardiolynx is based in Basel, Switzerland.

Cardiolynx AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Cardiolynx AG - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Cardiolynx AG, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Cardiolynx AG, Pharmaceuticals and Healthcare, Deal Details 10
Venture Financing 10
Cardiolynx Raises Funds Through Series D Financing Round 10
Cardiolynx Raises US$10.6 Million In Series B Financing 11
Cardiolynx Raises US$1.4 Million In Series A Financing 12
Cardiolynx Raises US$1.4 Million In Seed Financing Round 13
Cardiolynx AG - Key Competitors 14
Key Employees 15
Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17


List of Tables

Cardiolynx AG, Pharmaceuticals and Healthcare, Key Facts 1
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Cardiolynx AG, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Cardiolynx AG, Deals By Therapy Area, 2009 to YTD 2015 8
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Cardiolynx Raises Funds Through Series D Financing Round 10
Cardiolynx Raises US$10.6 Million In Series B Financing 11
Cardiolynx Raises US$1.4 Million In Series A Financing 12
Cardiolynx Raises US$1.4 Million In Seed Financing Round 13
Cardiolynx AG, Key Competitors 14
Cardiolynx AG, Key Employees 15


List of Figures

Cardiolynx AG, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 1
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Cardiolynx AG, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.